News
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 Apr 24
Movers
Cadrenal Therapeutics Receives FDA Orphan Drug Designation For Tecarfarin For Prevention Of Thromboembolism And Thrombosis In Patients With LVADs, RVADs, Biventricular Assist Devices, And Total Artificial Hearts
9 Apr 24
Biotech, News, FDA, General
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target
14 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Cadrenal Therapeutics Announces Q4 2023 Operating Expenses Totaled $1.16M; Cash Used In Operating Activities Totaled $694,000 During Q4 2023; As Of December 31, 2023, Cash Balances Were $8.5M
11 Mar 24
News
12 Health Care Stocks Moving In Friday's After-Market Session
23 Feb 24
Movers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
22 Feb 24
Movers
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
8 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Thursday's Intraday Session
8 Feb 24
Movers
Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial
8 Feb 24
News, Management
Press releases
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
11 Apr 24
Press Releases
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
9 Apr 24
Press Releases
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
11 Mar 24
Press Releases
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
26 Feb 24
Press Releases
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
8 Feb 24
Press Releases